Q3 FY2025 · Press release
ca251021-egm1 (1) · October 21, 2025 · 2 pages
Read Novo Nordisk A/S Class B's results firsthand
Preview this press release
Create a free account to start reading
Full documents are included with Professional
Novo Nordisk A/S Class B
42.18
USD
+1.99
(+4.95%)
Novo Nordisk A/S Class B Documents
Q3 FY2025 documents
Interim report
Novo Nordisk - Q3 2025 - Interim Report
38 pages
Nov 5, 2025
Interim report
38 pages
Nov 5, 2025
Presentation
Q3-2025-investor-presentation (1)
138 pages
Presentation
20251009_Akero_conf_call_slides (2)
8 pages
Presentation
12 pages
Presentation
138 pages
Press release
ca251021-egm1 (1)
2 pages
Oct 21, 2025
Press release
5 pages
Oct 9, 2025